These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23146489)

  • 1. Analytical validation of a homogeneous immunoassay for determination of mycophenolic acid in human plasma.
    Vergara Chozas JM; Sáez-Benito Godino A; Zopeque García N; García Pinteño S; Joumady I; Carrasco García C; Vara Gil F
    Transplant Proc; 2012 Nov; 44(9):2669-72. PubMed ID: 23146489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of the Immunochemical Methods, PETINIA and EMIT, With That of HPLC-UV for the Routine Monitoring of Mycophenolic Acid in Heart Transplant Patients.
    Kunicki PK; Pawiński T; Boczek A; Waś J; Bodnar-Broniarczyk M
    Ther Drug Monit; 2015 Jun; 37(3):311-8. PubMed ID: 25380305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of mycophenolic acid monitoring with PETINIA for prediction of adverse events in kidney transplant recipients.
    Ham JY; Jung HY; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD; Won DI; Song KE; Cho JH
    Scand J Clin Lab Invest; 2016 Jul; 76(4):296-303. PubMed ID: 26981890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of mycophenolic acid concentrations determined by a new PETINIA assay on the dimension EXL analyzer and a HPLC-UV method.
    Dasgupta A; Tso G; Chow L
    Clin Biochem; 2013 May; 46(7-8):685-7. PubMed ID: 23219740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a CE method for the determination of mycophenolic acid in human plasma: a comparison with HPLC.
    Carlucci F; Anzini M; Rovini M; Cattaneo D; Merlini S; Tabucchi A
    Electrophoresis; 2007 Nov; 28(21):3908-14. PubMed ID: 17922503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External Validation of a Limited Sampling Strategy for the Estimation of Mycophenolic Acid Exposure Between Different Assay Methods: PETINIA and HPLC Methods.
    Doki K; Yoshida K; Usui J; Takahashi K; Oda T; Yamagata K; Homma M
    Clin Transplant; 2024 Oct; 38(10):e15471. PubMed ID: 39324931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
    Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
    Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients.
    Cai W; Cai Q; Xiong N; Qin Y; Lai L; Sun X; Hu Y
    Transplant Proc; 2018 Jun; 50(5):1298-1304. PubMed ID: 29735215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
    Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
    Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a new enzymatic assay with a high-performance liquid chromatography/ ultraviolet detection method for therapeutic drug monitoring of mycophenolic acid in adult liver transplant recipients.
    Blanchet B; Taieb F; Conti F; Abbas H; Seydi I; Harcouet L; Dauphin A; Calmus Y; Tod M
    Liver Transpl; 2008 Dec; 14(12):1745-51. PubMed ID: 19025918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy.
    Weber LT; Shipkova M; Armstrong VW; Wagner N; Schütz E; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B
    Clin Chem; 2002 Mar; 48(3):517-25. PubMed ID: 11861442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.
    Tedesco-Silva H; Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Slade A; Schmouder R; Medina-Pestana JO
    Clin Transplant; 2010; 24(4):E116-23. PubMed ID: 20047618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
    Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
    Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
    Staatz CE; Tett SE
    Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
    Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
    Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients.
    Böhler T; Canivet C; Galvani S; Therville N; Salvayre R; Negre-Salvayre A; Durand D; Thomsen M; Rostaing L; Kamar N
    Int Immunopharmacol; 2008 May; 8(5):769-73. PubMed ID: 18387521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
    Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
    Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
    Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
    Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.